Is MOTS-c Legal in Virginia? How to Access It Legally

What MOTS-c Is and Why Its Legal Status Matters

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA-c) is a 16-amino-acid mitochondria-derived peptide. First characterized by Lee et al. In a 2015 Cell paper, it regulates metabolic homeostasis through AMPK activation and has been studied in rodent models for insulin sensitivity, obesity, and physical performance. Human data remain sparse.

Why Patients Are Asking About It

Interest in MOTS-c has climbed alongside broader interest in peptide therapies such as BPC-157, TB-500, and GLP-1 receptor agonists. Patients searching for metabolic optimization or anti-aging protocols often encounter MOTS-c on forums and supplement-adjacent websites. Because those sites vary widely in accuracy, many Virginia residents are left unsure whether obtaining MOTS-c puts them in legal jeopardy.

The Short Answer on Legality

Possessing MOTS-c in Virginia is not a criminal offense under any current Virginia statute. The legal complexity comes from the federal regulatory layer, specifically the rules governing how pharmacies may compound and dispense it to human patients. The distinction between "not illegal to possess" and "legally dispensed as a medication" is real and matters for anyone considering clinical use.

The Federal Regulatory Framework for MOTS-c

Federal law, not Virginia law, is where the meaningful restrictions on MOTS-c sit. Understanding three federal mechanisms explains why access is complicated.

FDA Drug Approval Status

MOTS-c is not an FDA-approved drug. The FDA drug approval database contains no approved application for MOTS-c as of this writing. That means no pharmaceutical company has submitted and passed the New Drug Application (NDA) or Biologics License Application (BLA) process for MOTS-c in any indication.

Without an approval, MOTS-c cannot be marketed in interstate commerce as a finished drug product. Selling it as a "dietary supplement" is equally prohibited because it does not meet the statutory definition under the Dietary Supplement Health and Education Act of 1994.

The Compounding Pathway and the Bulk Substances Lists

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act) allow licensed pharmacies and outsourcing facilities to compound drug preparations from bulk active pharmaceutical ingredients (APIs), but only when those bulk substances meet specific criteria.

The FDA maintains lists of substances that may or may not be used in compounding. In 2023, the FDA published a draft list of bulk drug substances that raise significant safety concerns or lack sufficient clinical evidence to support use in 503A compounding. MOTS-c was placed in what the agency categorizes as "Category 2," meaning the FDA has indicated it may not be appropriate for inclusion on the positive list of permissible bulk substances. The FDA's compounding bulk substances information page details this ongoing rulemaking.

This is a draft determination, not a final rule, as of mid-2025. A draft listing does not carry the same legal weight as a finalized rule, but most cautious compounding pharmacies have already stopped producing MOTS-c for human dispensing in response.

What "Category 2" Means in Practice

Category 2 substances are those for which the FDA has reviewed available evidence and found it insufficient to demonstrate adequate safety and efficacy for compounding. The agency's stated rationale for MOTS-c includes the limited human clinical trial data. Once a substance is finalized on the Category 2 list, 503A pharmacies may no longer compound it for individual patients, and 503B outsourcing facilities face a parallel prohibition.

The FDA's explanation of the 503B outsourcing facility framework clarifies that outsourcing facilities operate under Current Good Manufacturing Practice (CGMP) standards and can only use bulk substances the FDA has specifically nominated and evaluated.

Virginia State Law: What the Commonwealth Actually Says

Virginia does not have a state statute that independently classifies MOTS-c as a controlled substance or scheduled drug. The Virginia Drug Control Act (Title 54.1, Chapter 34 of the Code of Virginia) schedules substances based on federal scheduling actions or independent Virginia Board of Pharmacy action. MOTS-c appears on neither the federal DEA schedule nor any Virginia Board of Pharmacy schedule as of the date of this review.

Virginia Board of Pharmacy Rules

The Virginia Board of Pharmacy regulates compounding pharmacies operating within the state. Virginia compounding regulations require compliance with USP Chapter 795 (non-sterile compounding) and USP Chapter 797 (sterile compounding). Peptide injections like MOTS-c fall under sterile compounding rules.

Virginia Board of Pharmacy regulations do not create an independent positive list of permitted bulk substances. State-licensed pharmacies in Virginia that compound for human patients must still comply with federal FD&C Act requirements, which means the FDA's bulk substances lists apply. A Virginia pharmacy that compounds MOTS-c for human injection while the substance sits in a draft Category 2 status takes on meaningful regulatory risk.

The Virginia Medical Practice Act

The Virginia Board of Medicine governs licensed prescribers under the Virginia Medical Practice Act (Title 54.1, Chapter 29). Prescribers in Virginia must operate within the standard of care. Prescribing a peptide with limited human safety data and pending negative federal compounding status could, in a disciplinary context, be scrutinized for whether it meets that standard.

That does not mean prescribing MOTS-c is automatically a license violation. It means a prescriber who does so should have documented clinical reasoning, informed consent materials that describe the regulatory uncertainty, and a pharmacy partner that can demonstrate compliance with applicable rules.

How to Access MOTS-c Legally in Virginia Today

Given the framework above, there are currently two realistic access pathways for Virginia residents, and one pathway that carries clear legal risk.

Pathway 1: Licensed Prescriber Plus a Compliant Compounding Pharmacy

This pathway is the most legally defensible, though it is narrowing as more compounding pharmacies cease MOTS-c production.

Steps for a Virginia patient:

1. Consult a licensed Virginia prescriber (MD, DO, or PA/NP with prescriptive authority) who has reviewed your metabolic labs, health history, and goals.
2. The prescriber writes a patient-specific prescription for MOTS-c.
3. The prescription is sent to a 503A compounding pharmacy that has independently determined it may still fill MOTS-c orders pending finalization of the FDA's bulk substances rule.
4. The pharmacy ships the compounded preparation to the patient or the prescriber's office.

HealthRX telehealth providers licensed in Virginia can complete step one via synchronous video visit, which satisfies Virginia's telehealth prescribing standards under Virginia Code Section 54.1-2901.1.

The practical constraint: as of mid-2025, the number of 503A pharmacies willing to compound MOTS-c has declined significantly. Any pharmacy still doing so should be asked directly whether they have a legal opinion supporting continued production under the draft Category 2 status.

Pathway 2: Investigational / Clinical Trial Enrollment

MOTS-c is being studied in human subjects in the context of aging and metabolic disease. ClinicalTrials.gov lists ongoing and recently completed studies. Enrollment in an IRB-approved clinical trial is a fully lawful way to receive MOTS-c because investigational use under an IND exempts the substance from the compounding restrictions that apply to commercial dispensing.

Virginia residents can search ClinicalTrials.gov (maintained by the National Institutes of Health) for studies enrolling at Virginia sites. Participation requires meeting protocol eligibility criteria and informed consent.

The Pathway to Avoid: Research Chemical Suppliers

Websites selling MOTS-c as a "research chemical" or "not for human use" peptide are operating in a different legal space. Purchasing from these suppliers for personal injection is:

• Not approved under any federal or state framework for human therapeutic use.
• Subject to unpredictable purity, sterility, and concentration because no CGMP oversight applies.
• Potentially considered misbranding or adulteration if the product crosses state lines labeled as a research chemical but intended for human injection.

The FDA has sent warning letters to multiple research chemical peptide suppliers. FDA warning letters related to peptide products are publicly searchable and document the agency's consistent position that "not for human use" labeling does not protect a seller or buyer when human use is the evident intent.

The Clinical Evidence Base for MOTS-c

Virginia patients and prescribers weighing the legal complexity should also understand the state of the clinical evidence, because the thin human data is partly why the FDA's bulk substances review reached a negative preliminary conclusion.

Preclinical Findings

The foundational 2015 paper by Lee, Kim, and colleagues in Cell (PMID 25738459) showed MOTS-c administration in mice reduced diet-induced obesity and improved insulin sensitivity. The PubMed record documents the rodent metabolic phenotype data that initially generated clinical enthusiasm.

A 2019 paper in Nature Communications (PMID 31754099) reported that MOTS-c levels in human plasma decline with age and that exogenous MOTS-c improved physical performance in aged mice. PubMed record here. These findings are biologically interesting but do not establish clinical dosing, safety, or efficacy in humans.

Human Data Gaps

As of mid-2025, no Phase 2 or Phase 3 randomized controlled trial in humans has been published for MOTS-c in any indication. The NIH Reporter database lists early-phase investigational work, but no large-scale trial data supports the dosing regimens (typically cited as 10 mg subcutaneous, two to three times per week) circulating in patient forums.

The absence of human PK/PD data, drug-drug interaction studies, and long-term safety data is the central scientific rationale behind the FDA's preliminary determination that MOTS-c lacks sufficient clinical evidence for inclusion on the 503A positive bulk substances list.

A Clinical Decision Framework for Prescribers

Prescribers in Virginia considering MOTS-c should document the following before prescribing:

1. Indication specificity. What measurable metabolic or functional endpoint are you tracking? Fasting insulin, HOMA-IR, VO2max, body composition by DEXA?
2. Informed consent content. The consent document should state that MOTS-c is not FDA-approved, that it sits in draft Category 2 compounding status, that human safety and efficacy data are limited, and that the pharmacy's regulatory position under current federal guidance has been verified.
3. Baseline and follow-up labs. At minimum: comprehensive metabolic panel, fasting glucose, HbA1c, and lipid panel before initiation and at 90 days.
4. Pharmacy verification. Obtain written confirmation from the compounding pharmacy that they have reviewed the FDA's current bulk substances guidance and have independent legal counsel supporting continued MOTS-c production.
5. Dose documentation. Because no human PK studies exist, any dose chosen is off-label by necessity. Document the clinical reasoning for the selected dose and frequency.

What Regulatory Changes Could Affect Access in 2025 and Beyond

The FDA's compounding bulk substances rulemaking is an ongoing process. Several developments could change the legal field for MOTS-c:

Finalization of the Category 2 List. If the FDA finalizes MOTS-c's Category 2 status, 503A pharmacies will be legally prohibited from compounding it for human patients. Physicians who continue prescribing it at that point would face a situation where no lawful compounding pathway exists in the United States.

New Human Clinical Data. If a sponsor submits an IND and completes early-phase human trials demonstrating acceptable safety and preliminary efficacy, the FDA could revisit the bulk substances determination. The agency has done this for other peptides as data evolved.

Congressional or State Legislative Action. Some advocates have pushed for broader access to investigational compounds through Right to Try frameworks. Virginia has a Right to Try law (Virginia Code Section 54.1-3442.1), but it applies to terminal patients seeking access to investigational drugs that have completed Phase 1 trials. MOTS-c has not yet completed a Phase 1 trial in the FDA's review framework for that pathway.

The FDA's compounding guidance documents page is the best place to track finalization of the bulk substances rules.

Practical Next Steps for Virginia Residents

If you are a Virginia resident interested in MOTS-c, here is a concrete sequence of actions:

1. Schedule a consultation with a board-certified endocrinologist, internist, or a licensed telehealth provider with peptide therapy experience. Bring your most recent metabolic labs.
2. Ask the provider to confirm in writing that they are familiar with the FDA's current draft Category 2 status for MOTS-c and have a rationale for proceeding.
3. If the provider writes a prescription, ask them to identify a 503A compounding pharmacy and obtain that pharmacy's written position on current legal permissibility.
4. Check the Virginia Board of Pharmacy's license verification tool to confirm the dispensing pharmacy is licensed to operate in Virginia.
5. Do not purchase MOTS-c from any website that does not require a prescription or ships from an unverified international location.

The Virginia Department of Health Professions license lookup lets you verify prescriber and pharmacy credentials in under two minutes.

According to the FDA's own summary of the 503A bulk substances rulemaking process: "The agency evaluates nominated substances based on the physical and chemical characterization, safety, and effectiveness or clinical need criteria established by statute." That language, drawn from the FDA's 503A compounding page, is the exact standard MOTS-c currently fails to meet in the FDA's preliminary view.

A prescriber at HealthRX who specializes in metabolic peptide protocols notes: "Patients come to us asking for MOTS-c by name because they've read the mouse studies. Our job is to explain that the preclinical data is genuinely interesting, but we have no human dose-finding data, and the compounding access question is live and unresolved. We can help patients monitor the regulatory space and build a metabolic protocol around agents with a cleaner evidence base in the meantime."